{"transactions":[{"id":689278,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T18:30:46.000Z","date":"2026-08-11","kind":"other","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of restricted stock unit (RSU) awards."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":517917,"source":{"system":"sec-edgar","filing":"0001628280-26-056108","document":"wk-form4_1786559443.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026056108/wk-form4_1786559443.xml","form_type":"4"}},{"id":689277,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-12T18:30:46.000Z","date":"2026-08-11","kind":"other","planned":false,"acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of restricted stock unit (RSU) awards."}],"balance_after":40656,"source":{"system":"sec-edgar","filing":"0001628280-26-056108","document":"wk-form4_1786559443.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026056108/wk-form4_1786559443.xml","form_type":"4"}},{"id":743205,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":37659,"kind":"person","name":"Coughlin Timothy","position":1,"cik":"0001376043","reported_name":"Coughlin Timothy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2026-06-10T22:21:32.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares subject to the stock option vest and become exercisable  in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":16000,"derivative":{"exercise_price":8.51,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-26-042326","document":"wk-form4_1781130089.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026042326/wk-form4_1781130089.xml","form_type":"4"}},{"id":743204,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":37659,"kind":"person","name":"Coughlin Timothy","position":1,"cik":"0001376043","reported_name":"Coughlin Timothy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2026-06-10T22:21:32.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/3 of the shares subject to the stock option will vest and become exercisable on June 9, 2027, and the remaining shares will vest and become exercisable in 24 equal monthly installments thereafter."}],"balance_after":16000,"derivative":{"exercise_price":8.51,"expiration_date":"2036-06-08","underlying":"Common  Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-26-042326","document":"wk-form4_1781130089.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026042326/wk-form4_1781130089.xml","form_type":"4"}},{"id":743203,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":37659,"kind":"person","name":"Coughlin Timothy","position":1,"cik":"0001376043","reported_name":"Coughlin Timothy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common  Stock","published_at":"2026-06-10T22:21:32.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F3","text":"The RSUs will vest in full on the earlier of (i) June 9, 2027, or (ii) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":16000,"source":{"system":"sec-edgar","filing":"0001628280-26-042326","document":"wk-form4_1781130089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026042326/wk-form4_1781130089.xml","form_type":"4"}},{"id":743202,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":37659,"kind":"person","name":"Coughlin Timothy","position":1,"cik":"0001376043","reported_name":"Coughlin Timothy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common  Stock","published_at":"2026-06-10T22:21:32.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"1/3 of the RSUs will vest on June 9, 2027, and the remaining RSUs will vest in two equal annual installments thereafter."}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0001628280-26-042326","document":"wk-form4_1781130089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026042326/wk-form4_1781130089.xml","form_type":"4"}},{"id":754815,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":23669,"kind":"person","name":"Napolitano Janet","position":1,"cik":"0001821008","reported_name":"Napolitano Janet","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-02T21:35:21.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":3200,"price":9.45,"value":30240.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 27, 2025."}],"balance_after":21216,"source":{"system":"sec-edgar","filing":"0001628280-26-039943","document":"wk-form4_1780436119.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026039943/wk-form4_1780436119.xml","form_type":"4"}},{"id":755320,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":42482,"kind":"person","name":"Sabatini Brent","position":1,"cik":"0002037272","reported_name":"Sabatini Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,  Chief Accounting Officer"}}],"security":"Common  Stock","published_at":"2026-06-02T21:31:54.000Z","date":"2026-06-01","kind":"sale","planned":true,"acquired":false,"shares":379,"price":9.45,"value":3581.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 379 shares of common stock acquired by the Reporting Person on May 29, 2026 pursuant to an employee stock purchase program."}],"balance_after":61902,"source":{"system":"sec-edgar","filing":"0001628280-26-039938","document":"wk-form4_1780435911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2037272/000162828026039938/wk-form4_1780435911.xml","form_type":"4"}},{"id":760240,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2026-05-28T23:25:45.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The shares subject to the stock option will vest and become exercisable in full on May 27, 2027."}],"balance_after":16000,"derivative":{"exercise_price":9.1,"exercise_date":"2027-05-27","expiration_date":"2036-05-26","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-26-038966","document":"wk-form4_1780010743.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038966/wk-form4_1780010743.xml","form_type":"4"}},{"id":760239,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-28T23:25:45.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":39806,"source":{"system":"sec-edgar","filing":"0001628280-26-038966","document":"wk-form4_1780010743.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038966/wk-form4_1780010743.xml","form_type":"4"}},{"id":760238,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":23669,"kind":"person","name":"Napolitano Janet","position":1,"cik":"0001821008","reported_name":"Napolitano Janet","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2026-05-28T23:25:23.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares subject to the stock option will vest and become exercisable in full on May 27, 2027."}],"balance_after":16000,"derivative":{"exercise_price":9.1,"exercise_date":"2027-05-27","expiration_date":"2036-05-26","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-26-038965","document":"wk-form4_1780010721.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038965/wk-form4_1780010721.xml","form_type":"4"}},{"id":760237,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":23669,"kind":"person","name":"Napolitano Janet","position":1,"cik":"0001821008","reported_name":"Napolitano Janet","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-28T23:25:23.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":24416,"source":{"system":"sec-edgar","filing":"0001628280-26-038965","document":"wk-form4_1780010721.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038965/wk-form4_1780010721.xml","form_type":"4"}},{"id":760234,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2026-05-28T23:25:00.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The shares subject to the stock option will vest and become exercisable in full on May 27, 2027."}],"balance_after":16000,"derivative":{"exercise_price":9.1,"exercise_date":"2027-05-27","expiration_date":"2036-05-26","underlying":"Common  Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-26-038964","document":"wk-form4_1780010697.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038964/wk-form4_1780010697.xml","form_type":"4"}},{"id":760233,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-28T23:25:00.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":48656,"source":{"system":"sec-edgar","filing":"0001628280-26-038964","document":"wk-form4_1780010697.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038964/wk-form4_1780010697.xml","form_type":"4"}},{"id":760236,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2026-05-28T23:24:33.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares subject to the stock option will vest and become exercisable in full on May 27, 2027."}],"balance_after":16000,"derivative":{"exercise_price":9.1,"exercise_date":"2027-05-27","expiration_date":"2036-05-26","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-26-038963","document":"wk-form4_1780010671.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038963/wk-form4_1780010671.xml","form_type":"4"}},{"id":760235,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43527,"kind":"person","name":"Hatfield Jeffrey S.","position":1,"cik":"0001609879","reported_name":"Hatfield Jeffrey S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-28T23:24:33.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":39806,"source":{"system":"sec-edgar","filing":"0001628280-26-038963","document":"wk-form4_1780010671.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038963/wk-form4_1780010671.xml","form_type":"4"}},{"id":760232,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43526,"kind":"person","name":"Farid Ramy","position":1,"cik":"0001797707","reported_name":"Farid Ramy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2026-05-28T23:24:07.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares subject to the stock option will vest and become exercisable in full on May 27, 2027."}],"balance_after":16000,"derivative":{"exercise_price":9.1,"exercise_date":"2027-05-27","expiration_date":"2036-05-26","underlying":"Common  Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-26-038962","document":"wk-form4_1780010645.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038962/wk-form4_1780010645.xml","form_type":"4"}},{"id":760231,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43526,"kind":"person","name":"Farid Ramy","position":1,"cik":"0001797707","reported_name":"Farid Ramy","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-28T23:24:07.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":32000,"source":{"system":"sec-edgar","filing":"0001628280-26-038962","document":"wk-form4_1780010645.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038962/wk-form4_1780010645.xml","form_type":"4"}},{"id":760229,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2026-05-28T23:23:38.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The shares subject to the stock option will vest and become exercisable in full on May 27, 2027."}],"balance_after":16000,"derivative":{"exercise_price":9.1,"exercise_date":"2027-05-27","expiration_date":"2036-05-26","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-26-038961","document":"wk-form4_1780010616.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038961/wk-form4_1780010616.xml","form_type":"4"}},{"id":760228,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-28T23:23:38.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest in full on May 27, 2027."}],"balance_after":21333,"source":{"system":"sec-edgar","filing":"0001628280-26-038961","document":"wk-form4_1780010616.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026038961/wk-form4_1780010616.xml","form_type":"4"}},{"id":793885,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T16:35:41.000Z","date":"2026-05-01","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":10.0466,"value":221025.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.94 to $10.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1078391,"source":{"system":"sec-edgar","filing":"0001628280-26-029640","document":"wk-form4_1777912538.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026029640/wk-form4_1777912538.xml","form_type":"4"}},{"id":796867,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":50577,"kind":"person","name":"De Backer Marianne","position":1,"cik":"0001797819","reported_name":"De Backer Marianne","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-04-30T21:43:20.000Z","date":"2026-04-29","kind":"other","planned":false,"acquired":true,"shares":233532,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer without consideration for tax and estate planning purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held in the name of the Ureel-De Backer Family Trust, of which the Reporting Person and her spouse are Trustees."}],"balance_after":286650,"source":{"system":"sec-edgar","filing":"0001628280-26-029041","document":"wk-form4_1777585398.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026029041/wk-form4_1777585398.xml","form_type":"4"}},{"id":796866,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":50577,"kind":"person","name":"De Backer Marianne","position":1,"cik":"0001797819","reported_name":"De Backer Marianne","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-04-30T21:43:20.000Z","date":"2026-04-29","kind":"other","planned":false,"acquired":false,"shares":233532,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer without consideration for tax and estate planning purposes."}],"balance_after":714613,"source":{"system":"sec-edgar","filing":"0001628280-26-029041","document":"wk-form4_1777585398.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026029041/wk-form4_1777585398.xml","form_type":"4"}},{"id":813449,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":50577,"kind":"person","name":"De Backer Marianne","position":1,"cik":"0001797819","reported_name":"De Backer Marianne","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-04-07T20:50:56.000Z","date":"2026-04-06","kind":"sale","planned":true,"acquired":false,"shares":72559,"price":9.156,"value":664350.204,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an automatic and mandatory sale of shares under a  Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":948145,"source":{"system":"sec-edgar","filing":"0001628280-26-024098","document":"wk-form4_1775595054.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026024098/wk-form4_1775595054.xml","form_type":"4"}},{"id":819638,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-02T14:46:41.000Z","date":"2026-04-01","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":9.0735,"value":199617.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.87 to $9.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1100391,"source":{"system":"sec-edgar","filing":"0001628280-26-022971","document":"wk-form4_1775141198.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026022971/wk-form4_1775141198.xml","form_type":"4"}},{"id":829568,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":42482,"kind":"person","name":"Sabatini Brent","position":1,"cik":"0002037272","reported_name":"Sabatini Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,  Chief Accounting Officer"}}],"security":"Common  Stock","published_at":"2026-03-24T20:35:36.000Z","date":"2026-03-23","kind":"sale","planned":true,"acquired":false,"shares":7711,"price":9.12,"value":70324.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025."}],"balance_after":61902,"source":{"system":"sec-edgar","filing":"0001628280-26-020823","document":"wk-form4_1774384534.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2037272/000162828026020823/wk-form4_1774384534.xml","form_type":"4"}},{"id":830817,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":614,"kind":"person","name":"O'Byrne Jason","position":1,"cik":"0001871145","reported_name":"O'Byrne Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common  Stock","published_at":"2026-03-23T19:49:52.000Z","date":"2026-03-20","kind":"other","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer without consideration for estate planning purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held in the name of the O'Byrne Family Trust, of which the Reporting Person and his spouse are Trustees."}],"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001628280-26-020480","document":"wk-form4_1774295389.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026020480/wk-form4_1774295389.xml","form_type":"4"}},{"id":830816,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":614,"kind":"person","name":"O'Byrne Jason","position":1,"cik":"0001871145","reported_name":"O'Byrne Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common  Stock","published_at":"2026-03-23T19:49:52.000Z","date":"2026-03-20","kind":"other","planned":false,"acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer without consideration for estate planning purposes."}],"balance_after":160115,"source":{"system":"sec-edgar","filing":"0001628280-26-020480","document":"wk-form4_1774295389.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026020480/wk-form4_1774295389.xml","form_type":"4"}},{"id":867395,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T17:10:03.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":200,"price":9.98,"value":1996.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.97 to $9.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1122391,"source":{"system":"sec-edgar","filing":"0001628280-26-013630","document":"wk-form4_1772557800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026013630/wk-form4_1772557800.xml","form_type":"4"}},{"id":867394,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T17:10:03.000Z","date":"2026-03-02","kind":"sale","planned":true,"acquired":false,"shares":21800,"price":9.5039,"value":207185.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.97 to $9.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1122591,"source":{"system":"sec-edgar","filing":"0001628280-26-013630","document":"wk-form4_1772557800.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026013630/wk-form4_1772557800.xml","form_type":"4"}},{"id":879714,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2026-02-26T21:56:28.000Z","date":"2026-02-24","kind":"exercise","planned":true,"acquired":false,"shares":42377,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares vested and became exercisable in 36 equal monthly installments from October 5, 2017."}],"balance_after":0,"derivative":{"exercise_price":1.485,"expiration_date":"2027-10-05","underlying":"Common  Stock","underlying_shares":42377},"source":{"system":"sec-edgar","filing":"0001628280-26-012397","document":"wk-form4_1772142986.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026012397/wk-form4_1772142986.xml","form_type":"4"}},{"id":879713,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T21:56:28.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":200,"price":10.26,"value":2052.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."}],"balance_after":1144391,"source":{"system":"sec-edgar","filing":"0001628280-26-012397","document":"wk-form4_1772142986.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026012397/wk-form4_1772142986.xml","form_type":"4"}},{"id":879712,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T21:56:28.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":42177,"price":9.7521,"value":411314.3217,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.23 to $10.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1144591,"source":{"system":"sec-edgar","filing":"0001628280-26-012397","document":"wk-form4_1772142986.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026012397/wk-form4_1772142986.xml","form_type":"4"}},{"id":879711,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-26T21:56:28.000Z","date":"2026-02-24","kind":"exercise","planned":true,"acquired":true,"shares":42377,"price":1.485,"value":62929.845,"ownership":{"direct":true},"balance_after":1186768,"source":{"system":"sec-edgar","filing":"0001628280-26-012397","document":"wk-form4_1772142986.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026012397/wk-form4_1772142986.xml","form_type":"4"}},{"id":880017,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":42482,"kind":"person","name":"Sabatini Brent","position":1,"cik":"0002037272","reported_name":"Sabatini Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,  Chief Accounting Officer"}}],"security":"Common  Stock","published_at":"2026-02-26T21:56:06.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":1430,"price":9.5326,"value":13631.618,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an automatic and mandatory sale of shares under a  Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":69613,"source":{"system":"sec-edgar","filing":"0001628280-26-012396","document":"wk-form4_1772142963.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2037272/000162828026012396/wk-form4_1772142963.xml","form_type":"4"}},{"id":879705,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":614,"kind":"person","name":"O'Byrne Jason","position":1,"cik":"0001871145","reported_name":"O'Byrne Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common  Stock","published_at":"2026-02-26T21:55:39.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":1634,"price":9.5326,"value":15576.2684,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an automatic and mandatory sale of shares under a  Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":162615,"source":{"system":"sec-edgar","filing":"0001628280-26-012395","document":"wk-form4_1772142937.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026012395/wk-form4_1772142937.xml","form_type":"4"}},{"id":879709,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":35162,"kind":"person","name":"Eisner Mark","position":1,"cik":"0001834161","reported_name":"Eisner Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-26T21:55:19.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":1889,"price":9.82,"value":18549.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2025."}],"balance_after":154024,"source":{"system":"sec-edgar","filing":"0001628280-26-012394","document":"wk-form4_1772142916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026012394/wk-form4_1772142916.xml","form_type":"4"}},{"id":879708,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":35162,"kind":"person","name":"Eisner Mark","position":1,"cik":"0001834161","reported_name":"Eisner Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-26T21:55:19.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":1616,"price":9.5326,"value":15404.6816,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an automatic and mandatory sale of shares under a  Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":155913,"source":{"system":"sec-edgar","filing":"0001628280-26-012394","document":"wk-form4_1772142916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026012394/wk-form4_1772142916.xml","form_type":"4"}},{"id":879707,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":64498,"kind":"person","name":"de Verneuil Vanina","position":1,"cik":"0002036234","reported_name":"de Verneuil Vanina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel, Corp Sec"}}],"security":"Common  Stock","published_at":"2026-02-26T21:54:57.000Z","date":"2026-02-25","kind":"sale","planned":true,"acquired":false,"shares":13700,"price":9.82,"value":134534.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 2, 2025."}],"balance_after":112982,"source":{"system":"sec-edgar","filing":"0001628280-26-012393","document":"wk-form4_1772142894.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026012393/wk-form4_1772142894.xml","form_type":"4"}},{"id":879706,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":64498,"kind":"person","name":"de Verneuil Vanina","position":1,"cik":"0002036234","reported_name":"de Verneuil Vanina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel, Corp Sec"}}],"security":"Common  Stock","published_at":"2026-02-26T21:54:57.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":3117,"price":9.5326,"value":29713.1142,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an automatic and mandatory sale of shares under a  Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":126682,"source":{"system":"sec-edgar","filing":"0001628280-26-012393","document":"wk-form4_1772142894.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026012393/wk-form4_1772142894.xml","form_type":"4"}},{"id":879704,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":50577,"kind":"person","name":"De Backer Marianne","position":1,"cik":"0001797819","reported_name":"De Backer Marianne","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-26T21:54:33.000Z","date":"2026-02-24","kind":"sale","planned":true,"acquired":false,"shares":14762,"price":9.5326,"value":140720.2412,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an automatic and mandatory sale of shares under a  Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":1020704,"source":{"system":"sec-edgar","filing":"0001628280-26-012390","document":"wk-form4_1772142870.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026012390/wk-form4_1772142870.xml","form_type":"4"}},{"id":885455,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":42482,"kind":"person","name":"Sabatini Brent","position":1,"cik":"0002037272","reported_name":"Sabatini Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,  Chief Accounting Officer"}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2026-02-25T00:13:34.000Z","date":"2026-02-22","kind":"grant","planned":true,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter."}],"balance_after":50000,"derivative":{"exercise_price":7.56,"expiration_date":"2036-02-21","underlying":"Common  Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001628280-26-011331","document":"wk-form4_1771978411.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2037272/000162828026011331/wk-form4_1771978411.xml","form_type":"4"}},{"id":885454,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":42482,"kind":"person","name":"Sabatini Brent","position":1,"cik":"0002037272","reported_name":"Sabatini Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,  Chief Accounting Officer"}}],"security":"Common  Stock","published_at":"2026-02-25T00:13:34.000Z","date":"2026-02-23","kind":"sale","planned":true,"acquired":false,"shares":1829,"price":7.4528,"value":13631.1712,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents an automatic and mandatory sale of shares under a  Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person.v"}],"balance_after":71043,"source":{"system":"sec-edgar","filing":"0001628280-26-011331","document":"wk-form4_1771978411.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2037272/000162828026011331/wk-form4_1771978411.xml","form_type":"4"}},{"id":885453,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":42482,"kind":"person","name":"Sabatini Brent","position":1,"cik":"0002037272","reported_name":"Sabatini Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,  Chief Accounting Officer"}}],"security":"Common  Stock","published_at":"2026-02-25T00:13:34.000Z","date":"2026-02-22","kind":"grant","planned":true,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."}],"balance_after":72872,"source":{"system":"sec-edgar","filing":"0001628280-26-011331","document":"wk-form4_1771978411.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2037272/000162828026011331/wk-form4_1771978411.xml","form_type":"4"}},{"id":885008,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":614,"kind":"person","name":"O'Byrne Jason","position":1,"cik":"0001871145","reported_name":"O'Byrne Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2026-02-25T00:12:25.000Z","date":"2026-02-22","kind":"grant","planned":true,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter."}],"balance_after":110000,"derivative":{"exercise_price":7.56,"expiration_date":"2036-02-21","underlying":"Common  Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001628280-26-011330","document":"wk-form4_1771978342.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026011330/wk-form4_1771978342.xml","form_type":"4"}},{"id":885007,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":614,"kind":"person","name":"O'Byrne Jason","position":1,"cik":"0001871145","reported_name":"O'Byrne Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common  Stock","published_at":"2026-02-25T00:12:25.000Z","date":"2026-02-23","kind":"sale","planned":true,"acquired":false,"shares":2089,"price":7.4528,"value":15568.8992,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents an automatic and mandatory sale of shares under a  Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":164249,"source":{"system":"sec-edgar","filing":"0001628280-26-011330","document":"wk-form4_1771978342.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026011330/wk-form4_1771978342.xml","form_type":"4"}},{"id":885006,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":614,"kind":"person","name":"O'Byrne Jason","position":1,"cik":"0001871145","reported_name":"O'Byrne Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common  Stock","published_at":"2026-02-25T00:12:25.000Z","date":"2026-02-22","kind":"grant","planned":true,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 637 shares of common stock acquired by the Reporting Person on November 28, 2025, pursuant to an employee stock purchase program."}],"balance_after":166338,"source":{"system":"sec-edgar","filing":"0001628280-26-011330","document":"wk-form4_1771978342.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026011330/wk-form4_1771978342.xml","form_type":"4"}},{"id":885005,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":35162,"kind":"person","name":"Eisner Mark","position":1,"cik":"0001834161","reported_name":"Eisner Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2026-02-25T00:11:29.000Z","date":"2026-02-22","kind":"grant","planned":true,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter."}],"balance_after":110000,"derivative":{"exercise_price":7.56,"expiration_date":"2036-02-21","underlying":"Common  Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001628280-26-011329","document":"wk-form4_1771978287.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026011329/wk-form4_1771978287.xml","form_type":"4"}},{"id":885004,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":35162,"kind":"person","name":"Eisner Mark","position":1,"cik":"0001834161","reported_name":"Eisner Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-25T00:11:29.000Z","date":"2026-02-23","kind":"sale","planned":true,"acquired":false,"shares":2089,"price":7.4528,"value":15568.8992,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents an automatic and mandatory sale of shares under a  Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":157529,"source":{"system":"sec-edgar","filing":"0001628280-26-011329","document":"wk-form4_1771978287.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026011329/wk-form4_1771978287.xml","form_type":"4"}},{"id":885003,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":35162,"kind":"person","name":"Eisner Mark","position":1,"cik":"0001834161","reported_name":"Eisner Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-25T00:11:29.000Z","date":"2026-02-22","kind":"grant","planned":true,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."}],"balance_after":159618,"source":{"system":"sec-edgar","filing":"0001628280-26-011329","document":"wk-form4_1771978287.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026011329/wk-form4_1771978287.xml","form_type":"4"}},{"id":885002,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":64498,"kind":"person","name":"de Verneuil Vanina","position":1,"cik":"0002036234","reported_name":"de Verneuil Vanina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel, Corp Sec"}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2026-02-25T00:10:42.000Z","date":"2026-02-22","kind":"grant","planned":true,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter."}],"balance_after":110000,"derivative":{"exercise_price":7.56,"expiration_date":"2036-02-21","underlying":"Common  Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001628280-26-011328","document":"wk-form4_1771978240.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026011328/wk-form4_1771978240.xml","form_type":"4"}},{"id":885001,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":64498,"kind":"person","name":"de Verneuil Vanina","position":1,"cik":"0002036234","reported_name":"de Verneuil Vanina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel, Corp Sec"}}],"security":"Common  Stock","published_at":"2026-02-25T00:10:42.000Z","date":"2026-02-23","kind":"sale","planned":true,"acquired":false,"shares":4445,"price":7.4528,"value":33127.696,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents an automatic and mandatory sale of shares under a  Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":129799,"source":{"system":"sec-edgar","filing":"0001628280-26-011328","document":"wk-form4_1771978240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026011328/wk-form4_1771978240.xml","form_type":"4"}},{"id":885000,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":64498,"kind":"person","name":"de Verneuil Vanina","position":1,"cik":"0002036234","reported_name":"de Verneuil Vanina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel, Corp Sec"}}],"security":"Common  Stock","published_at":"2026-02-25T00:10:42.000Z","date":"2026-02-22","kind":"grant","planned":true,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,034 shares of common stock acquired by the Reporting Person on November 28, 2025 pursuant to an employee stock purchase program."}],"balance_after":134244,"source":{"system":"sec-edgar","filing":"0001628280-26-011328","document":"wk-form4_1771978240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026011328/wk-form4_1771978240.xml","form_type":"4"}},{"id":884995,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":50577,"kind":"person","name":"De Backer Marianne","position":1,"cik":"0001797819","reported_name":"De Backer Marianne","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2026-02-25T00:09:28.000Z","date":"2026-02-22","kind":"grant","planned":true,"acquired":true,"shares":570000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter."}],"balance_after":570000,"derivative":{"exercise_price":7.56,"expiration_date":"2036-02-21","underlying":"Common  Stock","underlying_shares":570000},"source":{"system":"sec-edgar","filing":"0001628280-26-011327","document":"wk-form4_1771978165.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026011327/wk-form4_1771978165.xml","form_type":"4"}},{"id":884994,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":50577,"kind":"person","name":"De Backer Marianne","position":1,"cik":"0001797819","reported_name":"De Backer Marianne","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-25T00:09:28.000Z","date":"2026-02-23","kind":"sale","planned":true,"acquired":false,"shares":19039,"price":7.4528,"value":141893.8592,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents an automatic and mandatory sale of shares under a  Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the Reporting Person."}],"balance_after":1035466,"source":{"system":"sec-edgar","filing":"0001628280-26-011327","document":"wk-form4_1771978165.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026011327/wk-form4_1771978165.xml","form_type":"4"}},{"id":884993,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":50577,"kind":"person","name":"De Backer Marianne","position":1,"cik":"0001797819","reported_name":"De Backer Marianne","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-25T00:09:28.000Z","date":"2026-02-22","kind":"grant","planned":true,"acquired":true,"shares":285000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."}],"balance_after":1054505,"source":{"system":"sec-edgar","filing":"0001628280-26-011327","document":"wk-form4_1771978165.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026011327/wk-form4_1771978165.xml","form_type":"4"}},{"id":897466,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":42482,"kind":"person","name":"Sabatini Brent","position":1,"cik":"0002037272","reported_name":"Sabatini Brent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP,  Chief Accounting Officer"}}],"security":"Common  Stock","published_at":"2026-02-18T20:38:11.000Z","date":"2026-02-13","kind":"sale","planned":true,"acquired":false,"shares":1530,"price":7.79,"value":11918.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an automatic and mandatory sale of shares under a  Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,290 and 485 shares of common stock acquired by the Reporting Person on May 30, 2025 and November 28, 2025, respectively, pursuant to an employee stock purchase program."}],"balance_after":47872,"source":{"system":"sec-edgar","filing":"0001628280-26-008984","document":"wk-form4_1771447089.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2037272/000162828026008984/wk-form4_1771447089.xml","form_type":"4"}},{"id":921931,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-03T17:28:45.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":7.7123,"value":169670.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.32 to $7.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1144391,"source":{"system":"sec-edgar","filing":"0001628280-26-004866","document":"wk-form4_1770139722.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026004866/wk-form4_1770139722.xml","form_type":"4"}},{"id":951604,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-05T18:57:28.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":5.9265,"value":130383.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.84 to $6.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1166391,"source":{"system":"sec-edgar","filing":"0001628280-26-000320","document":"wk-form4_1767639445.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828026000320/wk-form4_1767639445.xml","form_type":"4"}},{"id":981661,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-03T16:30:19.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":191854,"price":5.9826,"value":1147785.7404,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.2794 to $5.855. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments."}],"balance_after":13728924,"source":{"system":"sec-edgar","filing":"0001493152-25-025970","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225025970/ownership.xml","form_type":"4"}},{"id":983617,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-03T00:48:02.000Z","date":"2025-12-01","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":6.0032,"value":132070.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.87 to $6.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1188391,"source":{"system":"sec-edgar","filing":"0001628280-25-054884","document":"wk-form4_1764722880.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025054884/wk-form4_1764722880.xml","form_type":"4"}},{"id":985148,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T16:30:07.000Z","date":"2025-11-28","kind":"sale","planned":true,"acquired":false,"shares":61493,"price":6.44,"value":396014.92,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.3396 to $6.5398. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments."}],"balance_after":13920778,"source":{"system":"sec-edgar","filing":"0001493152-25-025571","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225025571/ownership.xml","form_type":"4"}},{"id":985147,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-01T16:30:07.000Z","date":"2025-11-26","kind":"sale","planned":true,"acquired":false,"shares":127938,"price":6.391,"value":817651.758,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.2498 to $6.50. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments."}],"balance_after":13982271,"source":{"system":"sec-edgar","filing":"0001493152-25-025571","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225025571/ownership.xml","form_type":"4"}},{"id":987201,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T16:30:21.000Z","date":"2025-11-25","kind":"sale","planned":true,"acquired":false,"shares":235971,"price":6.38,"value":1505494.98,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.12 to $6.6094. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments."}],"balance_after":14110209,"source":{"system":"sec-edgar","filing":"0001493152-25-025161","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225025161/ownership.xml","form_type":"4"}},{"id":987200,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-11-26T16:30:21.000Z","date":"2025-11-24","kind":"sale","planned":true,"acquired":false,"shares":227803,"price":6.1491,"value":1400783.4273,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.93 to $6.30. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments."}],"balance_after":14346180,"source":{"system":"sec-edgar","filing":"0001493152-25-025161","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225025161/ownership.xml","form_type":"4"}},{"id":995807,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":614,"kind":"person","name":"O'Byrne Jason","position":1,"cik":"0001871145","reported_name":"O'Byrne Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & Chief Financial Officer"}}],"security":"Common  Stock","published_at":"2025-11-18T19:47:11.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":6799,"price":5.557,"value":37782.043,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,500 shares of common stock acquired by the Reporting Person on May 30, 2025 pursuant to an employee stock purchase program."}],"balance_after":110701,"source":{"system":"sec-edgar","filing":"0001628280-25-052841","document":"wk-form4_1763495228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025052841/wk-form4_1763495228.xml","form_type":"4"}},{"id":1004919,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":64498,"kind":"person","name":"de Verneuil Vanina","position":1,"cik":"0002036234","reported_name":"de Verneuil Vanina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, General Counsel, Corp Sec"}}],"security":"Common  Stock","published_at":"2025-11-07T20:27:52.000Z","date":"2025-11-05","kind":"sale","planned":true,"acquired":false,"shares":2385,"price":5.16,"value":12306.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 5, 2024."}],"balance_after":78210,"source":{"system":"sec-edgar","filing":"0001628280-25-050592","document":"wk-form4_1762547269.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025050592/wk-form4_1762547269.xml","form_type":"4"}},{"id":1008250,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":64498,"kind":"person","name":"de Verneuil Vanina","position":1,"cik":"0002036234","reported_name":"de Verneuil Vanina","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and General Counsel"}}],"security":"Common  Stock","published_at":"2025-11-05T00:40:39.000Z","date":"2025-11-03","kind":"sale","planned":true,"acquired":false,"shares":1365,"price":5.863,"value":8002.995,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2,500 shares of common stock acquired by the Reporting Person on May 30, 2025 pursuant to an employee stock purchase program."}],"balance_after":80595,"source":{"system":"sec-edgar","filing":"0001628280-25-049159","document":"wk-form4_1762303236.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025049159/wk-form4_1762303236.xml","form_type":"4"}},{"id":1008248,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-04T16:58:05.000Z","date":"2025-11-03","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":5.6385,"value":124047.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.51 to $5.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1210391,"source":{"system":"sec-edgar","filing":"0001628280-25-048624","document":"wk-form4_1762275483.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025048624/wk-form4_1762275483.xml","form_type":"4"}},{"id":1011373,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-30T16:30:13.000Z","date":"2025-10-29","kind":"sale","planned":true,"acquired":false,"shares":100,"price":6.49,"value":649.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments."}],"balance_after":14573983,"source":{"system":"sec-edgar","filing":"0001493152-25-020240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225020240/ownership.xml","form_type":"4"}},{"id":1011372,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-30T16:30:13.000Z","date":"2025-10-28","kind":"sale","planned":true,"acquired":false,"shares":24453,"price":6.5025,"value":159005.6325,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.49 to $6.55. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments."}],"balance_after":14574083,"source":{"system":"sec-edgar","filing":"0001493152-25-020240","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225020240/ownership.xml","form_type":"4"}},{"id":1012598,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-28T16:30:11.000Z","date":"2025-10-27","kind":"sale","planned":true,"acquired":false,"shares":66403,"price":6.0477,"value":401585.4231,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.93 to $6.18. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments."}],"balance_after":14598536,"source":{"system":"sec-edgar","filing":"0001493152-25-019892","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225019892/ownership.xml","form_type":"4"}},{"id":1012597,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-28T16:30:11.000Z","date":"2025-10-24","kind":"sale","planned":true,"acquired":false,"shares":46696,"price":5.9595,"value":278284.812,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.92 to $6.0212. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments."}],"balance_after":14664939,"source":{"system":"sec-edgar","filing":"0001493152-25-019892","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225019892/ownership.xml","form_type":"4"}},{"id":1013840,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-24T16:30:12.000Z","date":"2025-10-23","kind":"sale","planned":true,"acquired":false,"shares":154383,"price":5.9898,"value":924723.2934,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.92 to $6.177. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments."}],"balance_after":14711635,"source":{"system":"sec-edgar","filing":"0001493152-25-019309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225019309/ownership.xml","form_type":"4"}},{"id":1013839,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-24T16:30:12.000Z","date":"2025-10-22","kind":"sale","planned":true,"acquired":false,"shares":144266,"price":6.1529,"value":887654.2714,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.08 to $6.2552. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments."}],"balance_after":14866018,"source":{"system":"sec-edgar","filing":"0001493152-25-019309","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225019309/ownership.xml","form_type":"4"}},{"id":1014749,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-22T16:30:08.000Z","date":"2025-10-21","kind":"sale","planned":true,"acquired":false,"shares":109675,"price":6.3002,"value":690974.435,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.12 to $6.4406. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments."}],"balance_after":15010284,"source":{"system":"sec-edgar","filing":"0001493152-25-018917","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225018917/ownership.xml","form_type":"4"}},{"id":1014748,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-22T16:30:08.000Z","date":"2025-10-20","kind":"sale","planned":true,"acquired":false,"shares":220535,"price":6.1998,"value":1367272.893,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.2961. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments."}],"balance_after":15119959,"source":{"system":"sec-edgar","filing":"0001493152-25-018917","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225018917/ownership.xml","form_type":"4"}},{"id":1016827,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-17T16:15:23.000Z","date":"2025-10-16","kind":"sale","planned":true,"acquired":false,"shares":12844,"price":6.1014,"value":78366.3816,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.1451. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments."}],"balance_after":15340494,"source":{"system":"sec-edgar","filing":"0001493152-25-018462","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225018462/ownership.xml","form_type":"4"}},{"id":1016826,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-17T16:15:23.000Z","date":"2025-10-15","kind":"sale","planned":true,"acquired":false,"shares":16671,"price":6.0702,"value":101196.3042,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.0765. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments."}],"balance_after":15353338,"source":{"system":"sec-edgar","filing":"0001493152-25-018462","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225018462/ownership.xml","form_type":"4"}},{"id":1019311,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-14T16:30:16.000Z","date":"2025-10-10","kind":"sale","planned":true,"acquired":false,"shares":2300,"price":6.0752,"value":13972.96,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.09. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments."}],"balance_after":15370009,"source":{"system":"sec-edgar","filing":"0001493152-25-018021","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225018021/ownership.xml","form_type":"4"}},{"id":1019310,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-14T16:30:16.000Z","date":"2025-10-09","kind":"sale","planned":true,"acquired":false,"shares":249060,"price":6.1428,"value":1529925.768,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.9625 to $6.35. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments."}],"balance_after":15372309,"source":{"system":"sec-edgar","filing":"0001493152-25-018021","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225018021/ownership.xml","form_type":"4"}},{"id":1020845,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-09T16:30:20.000Z","date":"2025-10-08","kind":"sale","planned":true,"acquired":false,"shares":466242,"price":6.0479,"value":2819784.9918,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.6101 to $6.325. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments."}],"balance_after":15621369,"source":{"system":"sec-edgar","filing":"0001493152-25-017612","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225017612/ownership.xml","form_type":"4"}},{"id":1020844,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-09T16:30:20.000Z","date":"2025-10-07","kind":"sale","planned":true,"acquired":false,"shares":72133,"price":5.6029,"value":404153.9857,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.52 to $5.675. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments."}],"balance_after":16087611,"source":{"system":"sec-edgar","filing":"0001493152-25-017612","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225017612/ownership.xml","form_type":"4"}},{"id":1022253,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-07T16:30:30.000Z","date":"2025-10-06","kind":"sale","planned":true,"acquired":false,"shares":73955,"price":5.6878,"value":420641.249,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.58 to $5.82. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments"}],"balance_after":16159744,"source":{"system":"sec-edgar","filing":"0001493152-25-017300","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225017300/ownership.xml","form_type":"4"}},{"id":1022252,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":72278,"kind":"organization","name":"SVF Endurance (Cayman) Ltd","position":1,"cik":"0001782338","reported_name":"SVF Endurance (Cayman) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72279,"kind":"organization","name":"SOFTBANK VISION FUND (AIV M1) L.P.","position":2,"cik":"0001755143","reported_name":"SOFTBANK VISION FUND (AIV M1) L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":15722,"kind":"organization","name":"SB INVESTMENT ADVISERS (UK) LTD","position":3,"cik":"0001731509","reported_name":"SB INVESTMENT ADVISERS (UK) LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-07T16:30:30.000Z","date":"2025-10-03","kind":"sale","planned":true,"acquired":false,"shares":450342,"price":5.5553,"value":2501784.9126,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person on September 3, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.355 to $5.823. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"SVF Endurance (Cayman) Limited is the record holder of the shares of Common Stock reported herein. SVF Endurance (Cayman) Limited is a wholly owned subsidiary of SoftBank Vision Fund (AIV M1) L.P. (\"SVF\"). SB Investment Advisers (UK) Limited (\"SBIA UK\") has been appointed as alternative investment fund manager (\"AIFM\") and is exclusively responsible for managing SVF in accordance with the Alternative Investment Fund Managers Directive and is authorized and regulated by the UK Financial Conduct Authority accordingly. As AIFM of SVF, SBIA UK is exclusively responsible for making all decisions related to the acquisition, structuring, financing, voting and disposal of SVF's investments"}],"balance_after":16233699,"source":{"system":"sec-edgar","filing":"0001493152-25-017300","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1782338/000149315225017300/ownership.xml","form_type":"4"}},{"id":1027364,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-02T15:53:03.000Z","date":"2025-10-01","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":5.8362,"value":128396.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.68 to $5.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1232391,"source":{"system":"sec-edgar","filing":"0001628280-25-043567","document":"wk-form4_1759420380.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025043567/wk-form4_1759420380.xml","form_type":"4"}},{"id":1049723,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-03T17:50:18.000Z","date":"2025-09-02","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":4.9914,"value":109810.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.88 to $5.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1254391,"source":{"system":"sec-edgar","filing":"0001197020-25-000005","document":"wk-form4_1756921815.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000119702025000005/wk-form4_1756921815.xml","form_type":"4"}},{"id":1076333,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-08-04T16:27:52.000Z","date":"2025-08-01","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":4.9863,"value":109698.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.89 to $5.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1276391,"source":{"system":"sec-edgar","filing":"0001628280-25-037344","document":"wk-form4_1754324866.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025037344/wk-form4_1754324866.xml","form_type":"4"}},{"id":1085548,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":35162,"kind":"person","name":"Eisner Mark","position":1,"cik":"0001834161","reported_name":"Eisner Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-07-17T22:46:56.000Z","date":"2025-07-17","kind":"sale","planned":true,"acquired":false,"shares":3586,"price":5.4738,"value":19629.0468,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 5, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.41 to $5.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":104618,"source":{"system":"sec-edgar","filing":"0001628280-25-035269","document":"wk-form4_1752792412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025035269/wk-form4_1752792412.xml","form_type":"4"}},{"id":1085547,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":35162,"kind":"person","name":"Eisner Mark","position":1,"cik":"0001834161","reported_name":"Eisner Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-07-17T22:46:56.000Z","date":"2025-07-15","kind":"sale","planned":true,"acquired":false,"shares":6796,"price":5.4682,"value":37161.8872,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units."}],"balance_after":108204,"source":{"system":"sec-edgar","filing":"0001628280-25-035269","document":"wk-form4_1752792412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025035269/wk-form4_1752792412.xml","form_type":"4"}},{"id":1095232,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-02T21:03:50.000Z","date":"2025-07-01","kind":"sale","planned":true,"acquired":false,"shares":22000,"price":5.1003,"value":112206.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.90 to $5.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1298391,"source":{"system":"sec-edgar","filing":"0001628280-25-034055","document":"wk-form4_1751490221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025034055/wk-form4_1751490221.xml","form_type":"4"}},{"id":1117959,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T22:39:33.000Z","date":"2025-06-09","kind":"other","planned":false,"acquired":true,"shares":14027,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of RSU awards. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1. However, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held by APNG 1. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG I. The Reporting Person may be deemed to beneficially own the shares held by APNG 1, and disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein."}],"balance_after":509917,"source":{"system":"sec-edgar","filing":"0001628280-25-030306","document":"wk-form4_1749508754.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025030306/wk-form4_1749508754.xml","form_type":"4"}},{"id":1117958,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":24127,"kind":"person","name":"MORE ROBERT J","position":1,"cik":"0001207792","reported_name":"MORE ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T22:39:33.000Z","date":"2025-06-09","kind":"other","planned":false,"acquired":false,"shares":14027,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares held by the Reporting Person for the benefit of Alta Partners NextGen Fund I, L.P. (APNG 1) were transferred by the Reporting Person for no consideration to APNG 1 in connection with the vesting of RSU awards. The Reporting Person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the Reporting Person may be deemed to beneficially own the shares held by APNG 1. However, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise."}],"balance_after":40656,"source":{"system":"sec-edgar","filing":"0001628280-25-030306","document":"wk-form4_1749508754.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025030306/wk-form4_1749508754.xml","form_type":"4"}},{"id":1119706,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common  Stock","published_at":"2025-06-07T00:26:07.000Z","date":"2025-06-06","kind":"other","planned":false,"acquired":true,"shares":10667,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer without consideration for tax planning purposes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held in the name of Nextquest, LLC, of which the Reporting Person is a managing member."}],"balance_after":10667,"source":{"system":"sec-edgar","filing":"0001628280-25-030078","document":"wk-form4_1749255960.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025030078/wk-form4_1749255960.xml","form_type":"4"}},{"id":1119705,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":16121,"kind":"person","name":"BISCHOFBERGER NORBERT W","position":1,"cik":"0001190273","reported_name":"BISCHOFBERGER NORBERT W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-07T00:26:07.000Z","date":"2025-06-06","kind":"other","planned":false,"acquired":false,"shares":10667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transfer without consideration for tax planning purposes."}],"balance_after":13333,"source":{"system":"sec-edgar","filing":"0001628280-25-030078","document":"wk-form4_1749255960.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025030078/wk-form4_1749255960.xml","form_type":"4"}},{"id":1127713,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2025-06-02T23:31:04.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The shares subject to the stock option will vest and become exercisable in full on May 30, 2026."}],"balance_after":16000,"derivative":{"exercise_price":4.94,"exercise_date":"2026-05-30","expiration_date":"2035-05-29","underlying":"Common  Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-25-028902","document":"wk-form4_1748907056.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025028902/wk-form4_1748907056.xml","form_type":"4"}},{"id":1127712,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":43528,"kind":"person","name":"Sigal Charles Elliott","position":1,"cik":"0001661908","reported_name":"Sigal Charles Elliott","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T23:31:04.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest in full on  May 30, 2026."}],"balance_after":31806,"source":{"system":"sec-edgar","filing":"0001628280-25-028902","document":"wk-form4_1748907056.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025028902/wk-form4_1748907056.xml","form_type":"4"}},{"id":1127710,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2025-06-02T23:28:45.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares subject to the stock option will vest and become exercisable in full on May 30, 2026."}],"balance_after":16000,"derivative":{"exercise_price":4.94,"exercise_date":"2026-05-30","expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-25-028900","document":"wk-form4_1748906919.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025028900/wk-form4_1748906919.xml","form_type":"4"}},{"id":1127709,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-02T23:28:45.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs will vest in full on  May 30, 2026."}],"balance_after":1320391,"source":{"system":"sec-edgar","filing":"0001628280-25-028900","document":"wk-form4_1748906919.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025028900/wk-form4_1748906919.xml","form_type":"4"}},{"id":1127708,"issuer":{"id":4522,"kind":"organization","name":"Vir Biotechnology, Inc.","symbol":"VIR"},"owners":[{"id":37277,"kind":"person","name":"Ramasastry Saira","position":1,"cik":"0001547959","reported_name":"Ramasastry Saira","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock  Option  (Right  to Buy)","published_at":"2025-06-02T23:27:26.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The shares subject to the stock option will vest and become exercisable in full on May 30, 2026."}],"balance_after":16000,"derivative":{"exercise_price":4.94,"exercise_date":"2026-05-30","expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0001628280-25-028898","document":"wk-form4_1748906840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828025028898/wk-form4_1748906840.xml","form_type":"4"}}],"next_cursor":"2025-06-02T23:27:26.000000Z,1127708"}